Nov 23, 2021
On November 9, 2021, ICER released its draft evidence report, “Tirzepatide for Type 2 Diabetes.” This is the first step in ICER’s process that is expected to conclude with the release of a final report in February 2022. Diabetes is a chronic condition in which a...
Nov 3, 2021
During the October 20, 2021, Senate Finance Hearing, Health Insurance Coverage in America: Current and Future Role of Federal Programs, the areas where each party agrees to disagree are stark, but the places where change for patients is possible exists. It is our aim...
Oct 14, 2021
On August 24, 2021, ICER released a revised version of a final evidence report from 2018 evaluating the clinical and cost effectiveness of three emerging treatments for hereditary angioedema. Unfortunately, while ICER tried to update its analysis — supposedly to...
Sep 27, 2021
On August 18, 2021, ICER released its draft evidence report, “Tezepelumab for Severe Asthma: Effectiveness and Value.” This is the first step in ICER’s standard process that – after a period of public comment – will result in the release of final evidence report,...
Sep 1, 2021
On August 18, 2021, ICER released its draft evidence report, “Mavacamten for Hypertrophic Cardiomyopathy: Effectiveness and Value.” This is the first step in ICER’s process that, if the announced schedule holds, will lead to the release of final evidence report in...
Aug 23, 2021
On August 17, 2021, ICER issued a Final Evidence Report on the clinical and cost-effectiveness of new treatments for atopic dermatitis (more commonly referred to as eczema). After following its typical process for gathering and reviewing data, ICER concluded that the...
